Results for “”

Entry Author Date Location
Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3 11/04/19 San Diego
Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More 11/01/19 National
Pinteon Gets $17M to Tackle Tau in Alzheimer’s, Other Brain Diseases 10/31/19 Boston
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug 10/31/19 Boston
FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns 10/30/19 National
Disc Medicine Launches With $50M to Advance New Anemia Treatments 10/29/19 Boston
With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer 10/28/19 New York
Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund 10/28/19 Wisconsin
UK Regulator Has “Competition Concerns” Over Illumina-PacBio Tie-Up 10/25/19 San Diego
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
Former Quartet, Knewton Exec David Liu Joins Sonde Health as CEO 10/24/19 Boston
Acorda Cuts Staff 25% and Restructures to Keep Focus on Parkinson’s Drug 10/24/19 New York
Xconomy Awards Boston 2019 Honors Best in Life Sciences: Slideshow 10/23/19 Boston
Biogen Reverses Course on Alzheimer’s Drug Analysis, Plans FDA Filing 10/22/19 Boston
Vertex Stock Up on Quick FDA OK For 3-Drug Cystic Fibrosis Therapy 10/22/19 Boston
SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study 10/21/19 Seattle
Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer 10/21/19 Boston
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More 10/18/19 National
Plexium Debuts With $28M and a New Take on Protein Degradation Drugs 10/17/19 San Diego
Healx Bags $56M to Advance Affordable, AI-Based Orphan Drugs 10/17/19 National
Nuance & Microsoft Team Up on Conversational AI for Doctors’ Offices 10/17/19 Boston
ArsenalBio Launches With $85M for “Programmable” T Cell Therapies 10/17/19 San Francisco
Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test 10/16/19 Indiana
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms 10/16/19 Boston
Led by Gilead Veteran Riva, Glenmark’s Ichnos Steps Out on Its Own 10/15/19 New York
Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug 10/15/19 Boston
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades 10/11/19 Indiana
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More 10/11/19 San Francisco
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More 10/11/19 National
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma 10/10/19 Boston
Page 2 of 1954 « previous page · next page »